List of Ubrelvy drug patents

Ubrelvy is owned by Allergan.

Ubrelvy contains Ubrogepant.

Ubrelvy has a total of 5 drug patents out of which 0 drug patents have expired.

Ubrelvy was authorised for market use on 23 December, 2019.

Ubrelvy is available in tablet;oral dosage forms.

Ubrelvy can be used as acute treatment of migraine with headache, with or without aura in adults, acute treatment of migraine with or without aura in adults.

Drug patent challenges can be filed against Ubrelvy from December, 2023.

The generics of Ubrelvy are possible to be released after 30 January, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9499545 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8912210 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(8 years from now)

US10117836 ALLERGAN Tablet formulation for CGRP active compounds
Jan, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in